Vivanza Biosciences' Q1 FY 2026-27 Quarterly Results

Result Summary

• Vivanza Biosciences Ltd reported a 51.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 7.8%.
• Its expenses for the quarter were up by 42.1% QoQ and 7.0% YoY.
• The net profit decreased 133.3% QoQ and increased 66.7% YoY.
• The earnings per share (EPS) of Vivanza Biosciences Ltd stood at 0.04 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vivanza Biosciences Ltd is a company engaged in the biosciences industry. The company is likely involved in the development and commercialization of bioscience-related products or services. However, detailed information regarding the specific products, services, or recent major developments of Vivanza Biosciences Ltd is not available from the data provided. The company operates within a dynamic sector characterized by continuous innovation and regulatory oversight, which can significantly influence its operational and financial performance.

Revenue

Vivanza Biosciences Ltd reported a total income of ₹9.66 crores in Q1FY27. This reflects a robust quarter-over-quarter (QoQ) increase of 51.6% from ₹6.37 crores in Q4FY26. Additionally, there is a year-over-year (YoY) growth of 7.8% compared to ₹8.96 crores in Q1FY26. The notable QoQ growth suggests a strong start to the fiscal year, highlighting the company's ability to enhance its revenue generation compared to the previous quarter. The YoY growth further solidifies its revenue expansion efforts compared to the same quarter last year.

Profitability

In Q1FY27, Vivanza Biosciences Ltd achieved a profit before tax of ₹0.18 crores, a significant improvement from the loss of ₹0.30 crores in Q4FY26. The profit before tax also doubled from ₹0.09 crores in Q1FY26, indicating a 100% YoY increase. The company incurred a tax expense of ₹0.04 crores in Q1FY27, reduced from ₹0.15 crores in Q4FY26, reflecting a decrease of 73.3% QoQ. The profit after tax stood at ₹0.15 crores for Q1FY27, recovering from a loss of ₹0.45 crores in the previous quarter, with a 66.7% YoY increase from ₹0.09 crores in Q1FY26. The earnings per share (EPS) improved to ₹0.04, up from a negative ₹0.11 in Q4FY26, and doubled from ₹0.02 in Q1FY26.

Operating Metrics

The total expenses for Vivanza Biosciences Ltd in Q1FY27 were ₹9.49 crores, marking a 42.1% increase from ₹6.68 crores in Q4FY26. Compared to Q1FY26, the expenses increased by 7.0% from ₹8.87 crores. The substantial QoQ increase in expenses can be attributed to various operational factors that are not specified within the provided data. Despite the increase in expenses, the company successfully transitioned from a loss to a profit, as reflected in its profitability metrics. The data provided does not include specific details about the company's operating metrics like P/E ratio, debt-to-equity ratio, or current ratio, thus limiting the analysis to the direct financial performance metrics available.